Authors
Latest:
Long-Term Results of Post-Prostatectomy RadiotherapyDouglas M. Dahl, MD, FACS, discusses the long-term results of post-prostatectomy radiotherapy.
Latest:
Evaluating Cytoreductive Approaches in MPNsDouglas Tremblay, MD, discusses the different cytoreduction approaches available to patients with myeloproliferative neoplasms and their safety profiles.
Latest:
Phase II ADAPT Trial in Patients With HER2+ and HR+ Early Breast CancerDouglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplantation, Department of Medicine, medical oncologist, University of Minnesota, discusses the results of the phase II ADAPT trial.
Latest:
Implementing EMR in Clinical Practice for Patients Receiving CAR T-Cell TherapyDylan Essner explains how Epic, an electronic medical record, can be used by nurses and oncology providers who are treating patients with chimeric antigen receptor T-cell therapy.
Latest:
Usmani Projects a Future of CAR T in Community for Myeloma and Other CancersDuring a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR T-cell therapies in multiple myeloma and beyond.
Latest:
Genomic Markers in Prostate CancerE. David Crawford, MD, professor, urology, radiation oncology, University of Colorado, discusses genomic markers in prostate cancer.
Latest:
Immune Checkpoint Inhibition in Breast CancerEdith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, comments on immune checkpoint inhibition for the treatment of breast cancer.
Latest:
A Phase III Trial Evaluating Iomab-B Prior to HCT in Relapsed/Refractory AMLEdward Agura, MD, Texas Oncology - Baylor Charles A. Sammons Cancer Center Blood and Marrow Transplant, discusses the phase III SIERRA trial, which is an ongoing trial investigating targeted conditioning of Iomab-B prior to allogeneic hematopoietic cell transplantation versus conventional care in patients with relapsed/refractory acute myeloid leukemia (AML).
Latest:
First-Line Combination Immunotherapy plus Chemotherapy in mNSCLCEdward B. Garon, MD, Professor of Medicine, and Director of the Thoracic Oncology group at the David Geffen School of Medicine at UCLA, reviews key clinical trial data and explains the rationale of using combination IO therapies in the treatment of non-small cell lung cancer (NSCLC).
Latest:
The Mechanism of Action and Development of Moxetumomab PasudotoxEdward Bradley, MD, gives an overview of the mechanism of action and development of moxetumomab pasudotox, a monoclonal antibody directed at CD22.
Latest:
Future Directions of Canakinumab and Unmet Needs in NSCLCEdward B. Garon, MD, MS, discusses data from the phase 3 CANOPY-A study and what they mean for the future of canakinumab for patients with non–small cell lung cancer.
Latest:
Future Treatment Approaches for HCCClosing out their discussion on the management of hepatocellular carcinoma, panelists discuss future novel therapies that may impact the treatment landscape.
Latest:
Better Computing Devices Are on the WayToday, oncologists and their patients face disruptive changes in healthcare practice, medical research, governmental oversight and regulation, business practices, and physician –patient communication—changes brought on by the growth and merging of the fields of information technology, medical technology, medical practice, biology, and physics.
Latest:
The Benefits of ASCO's TAPUR TrialEdward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the prospective benefits of the TAPUR clinical trial, which is being conducted by ASCO.
Latest:
Dr. Posadas Discusses Darolutamide in Castration-Resistant Prostate CancerEdwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor, Medicine, Cedars-Sinai Medical Center, discusses key takeaways from the ARAMIS trial of darolutamide in high-risk nonmetastatic castration-resistant prostate cancer.
Latest:
A Phase Ib Study of Abiraterone Plus Docetaxel for mCRPCEdwin M. Posadas, MD, FACP, discusses the results of a phase Ib study that looked at abiraterone and docetaxel for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Latest:
Modern Approaches to Treating Neuroendocrine TumorsEileen M. O’Reilly, MD, discusses the current treatment landscape for neuroendocrine tumors.
Latest:
Areas of Future Research Focus in Pancreatic CancerEileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses areas she believes will be the focus of future research in pancreatic cancer.
Latest:
Predicting Risk of Recurrence for Women With DCISEileen Rakovitch, MD, associate professor, radiation oncologist, Sunnybrook Health Sciences Centre, Toronto, Ontario, discusses predicting risk of recurrence in women with DCIS.
Latest:
Cervical Cancer Screening in Low-Resource CountriesElectra D. Paskett, PhD, Professor, College of Medicine, The Ohio State University, discusses screening for cervical cancer.
Latest:
Recurrence and Tailoring Radiotherapy Following Neoadjuvant ChemotherapyEleftherios Mamounas, MD, MPH, discusses locoregional recurrence and tailoring radiotherapy following neoadjuvant chemotherapy.
